January 27, 2026

Trispecific Antibody Earns FDA Fast Track Designation in Multiple Myeloma – CancerNetwork

January 27, 2026

FDA Fast Tracks IBI3003 For Relapsed/Refractory Myeloma – Cure Today

January 27, 2026

FDA Approves Daratumumab Quadruplet for Transplant-Ineligible Myeloma – Targeted Oncology

January 27, 2026

FDA Approves Daratumumab and Hyaluronidase-fihj With Quadruplet Regimen for Newly Diagnosed Multiple Myeloma – Pharmacy Times

January 27, 2026

FDA Approves Darzalex Faspro-VRd For Newly Diagnosed, Transplant Ineligible Multiple Myeloma – Cure Today